# Sunitinib Malate in Refractory Germ Cell Tumors

> **NCT00912912** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 5 (actual)

## Conditions studied

- Genitourinary Disease

## Interventions

- **DRUG:** Sunitinib Malate

## Key facts

- **NCT ID:** NCT00912912
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2016-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00912912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00912912, "Sunitinib Malate in Refractory Germ Cell Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00912912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*